Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells Ã¢ÂÂ A Mini-reviewRadosław Kujawski1*, Justyna Baraniak2, Marcin Ożarowski2,3, Małgorzata Kujawska4, Magdalena Borowska1, Malgorzata Kania2, Joanna Bartkowiak-Wieczorek5, Agnieszka Sobczak6, Agnieszka Gryszczyńska2, Katarzyna Manikowska1, Joanna Liberska1, Joanna Cichocka7, Michał Szulc1 and Piotr Ruszkowski1
- *Corresponding Author:
- Radosław Kujawski
Department of Pharmacology, Poznan University of Medical Science
Rokietnicka 5a Str., 60-806 Poznań, Poland
E-mail: [email protected]
Received date: March 17, 2017; Accepted date: May 10, 2017; Published date: May 17, 2017
Citation: Kujawski R, Baraniak J, Ozarowski M, Kujawska M, Borowska M, et al. (2017) Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells – A Mini-review. Altern Integr Med 6:238. doi: 10.4172/2327-5162.1000238
Copyright: © 2017 Kujawski R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Despite the increasing number of studies on the molecular actions of quercetin and curcumin, their anticancer efficacy, safety and molecular aspects of chemopreventive action in the ovarian cancer prophylaxis or treatment and also their potential in the sensitization to cytostatics used in the clinical practice remains still not clearly understood.
Based on basic studies we have summarized evidences for inhibitory activities of several often studied plantorigin bio-active compounds (mostly quercetin and curcumin) against ovarian cancer cells proliferation, their mechanisms of action as well as their strong potential to sensitization of ovarian cancer cells to the presence of several platinum-based cytostatics - cisplatin and oxaliplatin. Up to date only several dietary, clinical (cohort and case–control) studies evaluating the association of some flavonoids (mostly nonisoflavones) and its subgroup components consumption and ovarian cancer risk were already performed. According to the researchers, there has been no association between ovarian cancer risk and total nonisoflavone flavonoids intake. There is a still an insufficient amount of data designed to explain the effect of quercetin or curcumin (alone or together) on ovarian cancer development and/or its chemotherapy. Obtained results provide limited support for an association between nonisoflavone flavonoids intake and ovarian cancer risk, therefore there is a need for further and more accurate studies to be confirmed. We are of the opinion that this paper will contribute to a better understanding of the molecular basis for positive interactions between concomitant usage of quercetin or curcumin with above-mentioned cytostatics and other bio-active agents. This work may also contribute to an increase in the number of preclinical studies or other clinical, dietary trials using these or other phenolic / alkaloid, plant-origin constituents in order to investigate efficiency and safety of pharmacotherapy of ovarian cancer patients.